Over the last decade, the world of hemophilia has experienced an unprecedented therapeutic advance,...
Read More
New treatment possibilities and modalities are now available globally for patients with haemophilia requiring...
Introduction: Eptacog beta is a new recombinant activated human factor VII bypass- ing agent...
Predicting individual effects of switching from standard half-life (SHL) to extended half-life (EHL) FVIII/FIX...
Introduction: The phase 2/3 PROTECT VIII main study demonstrated efficacy and safety of BAY 94-9027...
Regular prophylaxis with exogenous factor VIII (FVIII) is recommended for individuals with severe haemophilia...
Introduction: Treatment optimization in haemophilia A can be achieved by choice of FVIII product...
The performance of surgery and invasive procedures in patients with haemophilia is currently facing new...
Against a background of a rapidly evolving treatment landscape, a contemporary, evidence-based consolidated understanding...
Abstract Background: Despite recent therapeutic advances, life expectancy in persons with congenital hemophilia A...